Acquisition of ADX-N05

Expanding our sleep/narcolepsy development pipeline

Overview Presentation

January 13, 2014

Jazz Pharmaceuticals®

Innovation that performs

Forward-Looking Statements

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This presentation contains forward-looking statements, including, but not limited to, statements related to the therapeutic and commercial potential of ADX-N05, planned future discussions with the U.S. Food and Drug Administration concerning Jazz Pharmaceuticals' anticipated development of ADX-N05, potential future clinical trials and other development of ADX-N05 planned to be conducted by the company and the anticipated timing thereof, including the indications the company plans to pursue, potential commercialization of ADX-N05 by the company, the company's pipeline and portfolio growth strategy, expected patent protection for ADX-N05 and the potential extension of that patent protection, and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the difficulty and uncertainty of pharmaceutical product development, including the timing and cost thereof, the risk that results from early clinical trials may not be predictive of results obtained in later and larger Phase 3 clinical trials and the uncertainty of clinical success and regulatory approval; the company's ability to successfully manage the risks associated with integrating ADX-N05 and any other products or product candidates the company may acquire in the future into the company's product portfolio, including the availability of funding to complete the development of, obtain regulatory approval for and commercialize ADX-N05 and any other potential future acquired product candidates; the possibility that the company may fail to realize the anticipated benefits from ADX-N05; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; protecting and expanding the company's intellectual property rights; and possible restrictions on the Company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and future filings and reports by the company. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in its expectations.

Strategic Rationale

Jazz Pharmaceuticals®
Innovation that performs

ADX-N05: Strategic Fit

Adds late-stage compound to development pipeline

Differentiated Molecule	✓ In two Phase 2 clinical trials, ADX-N05 demonstrated a highly statistically significant benefit vs. placebo in patients with excessive daytime sleepiness (EDS) associated with narcolepsy ✓ The mechanism of action of ADX-N05 appears distinct from modafinil and traditional stimulants that are used in patients with EDS associated with narcolepsy
Targeted Patient and Physician Audience	✓ Would add to our sleep franchise and utilize our clinical and commercial expertise in the sleep field to help drive value to patients ✓ Expected physician audience: primarily sleep specialists; expect synergy with Xyrem call universe
Significant Unmet Medical Need	✓ Continues commitment to patients with narcolepsy/sleep-related disorders ✓ Other wake-promoting agents are often inadequate in managing EDS[1]
Worldwide Rights	✓ Worldwide development, manufacturing and commercialization rights, excluding certain countries in Asia[2]
Lower-risk Development Opportunity	✓ Phase 2 narcolepsy trials enrolled a total of 126 patients; primary and secondary endpoints met with no unexpected safety findings to date ✓ Large safety database: more than 500 patient exposures
Exclusivity	✓ Patent protection is expected through 2027, with potential to lengthen at approval by patent term extension

[1] Guilleminault et al. Eur J Neurol. 2000;7:381-4; personal communication from J. Black et al, Stanford Sleep Patient Survey.
[2] SK Biopharmaceuticals retains rights in Korea, Japan, China, Taiwan, Singapore, Indonesia, India, Philippines, Thailand, Malaysia, Vietnam and Hong Kong.

ADX-N05: A late-stage opportunity to build upon our expertise in sleep medicine

- Orphan drug designation in US
- Phase 2 clinical trials completed for excessive daytime sleepiness (EDS) associated with narcolepsy:
  - Phase 2a study demonstrated highly statistically significant results on the primary and secondary efficacy endpoints in patients with narcolepsy.
  - Phase 2b data confirm Phase 2a study results; plan to submit data for presentation at a medical meeting in 2014
- Based on efficacy and tolerability clinical data to date, other development opportunities include EDS associated with obstructive sleep apnea
- Worldwide development, manufacturing and commercial rights to ADX-N05, excluding certain countries in Asia[1]

[1] SK Biopharmaceuticals retains rights in Korea, Japan, China, Taiwan, Singapore, Indonesia, India, Philippines, Thailand, Malaysia, Vietnam and Hong Kong.

Jazz Pharmaceuticals Clinical Development Pipeline



EDS = Excessive Daytime Sleepiness, OSA = Obstructive Sleep Apnea; ALL = Acute Lymphoblastic Leukemia, IV = Intravenous, AYA = Adolescents and Young Adults, aGvHD = Acute Graft vs. Host Disease

Clinical Data Overview

Jazz Pharmaceuticals®
Innovation that performs

ADX-N05: Phase 2a Design

- Phase 2a, 4-week, double-blind, placebo-controlled, 2-period, crossover
- Patients with documented excessive daytime sleepiness due to narcolepsy (as per ICSD-2)
- 33 patients randomized



Primary Endpoints:

- Change from Baseline in the average sleep latency time across 4 trials as determined from the Maintenance of Wakefulness Test (MWT)

Secondary Endpoints:

- Change from Baseline in Epworth Sleepiness Scale (ESS) scores
- Clinical Global Impression (CGI) Change scores

ICSD-2 = International Classification of Sleep Disorders, Second Edition

ADX-N05: Phase 2a Efficacy Outcomes

Primary Endpoint: Change from Baseline in average sleep latency from 4 Maintenance of Wakefulness Test (MWT) trials administered 2 hours apart



Secondary Endpoint: Change from Baseline at Weeks 1, 2, 3, 4 for Epworth Sleepiness Scales (ESS)



RK Bogan et al, Poster 0747, Presented at the 27th Annual Meeting of the Associated Professional Sleep Societies June 1-5, 2013, Baltimore, MD

Jazz Pharmaceuticals

ADX-N05: Phase 2a Adverse Events (≥5% incidence)

Adverse Event	ADX-N05 (Combined)[1] N=33
Patients with ≥ 1 AE	**14 (42%)**
Nausea	4 (12%)
Headache	3 (9%)
Non-cardiac chest discomfort	3 (9%)
Anxiety	2 (6%)
Decreased appetite	2 (6%)
Initial insomnia	2 (6%)
Insomnia	2 (6%)
Muscle tightness	2 (6%)

[1]150 mg/day and 300 mg/day combined

RK Bogan et al, Poster 0747, Presented at the 27th Annual Meeting of the Associated Professional Sleep Societies June 1-5, 2013, Baltimore, MD

ADX-N05: Phase 2b Design

- 12-week, double-blind, placebo-controlled, parallel design
- Patients with documented excessive daytime sleepiness due to narcolepsy (as per ICSD-2)
- Patients on ADX-N05 are started at 150mg and titrated to 300mg at the end of week 4
- 93 patients randomized



Primary Endpoints:

- Change from Baseline in the average sleep latency time as determined from the Maintenance of Wakefulness Test (MWT)
- Clinical Global Impression (CGI) Change scores at last assessment

Secondary Endpoints Included:

- Change from Baseline in Epworth Sleepiness Scale (ESS) scores
- Patient Global Impression (PGI) Change scores

ADX-N05: Phase 2b Results
Consistent magnitude of effect between Phase 2a and 2b

The Phase 2b data supports findings from Phase 2a

- Highly statistically significant results at both 4 weeks and 12 weeks / last assessment on the endpoints of MWT, CGI and ESS
- The results demonstrate a robust and consistent alerting effect highly consistent with Phase 2a results
- The dose range of 150 to 300mg was generally well tolerated
- Plan to submit Phase 2b data for presentation at a medical meeting in 2014

MWT = Maintenance of Wakefulness Test; CGI = Clinical Global Impression; ESS = Epworth Sleepiness Scale

ADX-N05: Preliminary Clinical Development Program

Anticipated Activities

- End of Phase 2 Meeting with FDA to discuss development program
  - Targeted for mid-2014
- Initiate Phase 3 clinical program
  - EDS associated with narcolepsy
  - EDS associated with OSA

Commercial Opportunity

EDS in Narcolepsy and OSA

Jazz Pharmaceuticals®
Innovation that performs

ADX-N05: Significant Commercial Opportunity
Potential to address substantial unmet medical need



Many patients with EDS associated with narcolepsy remain inadequately controlled on wake-promoting therapies

Source: Silber et al., SLEEP Vol. 25, No 2, 2002; Jazz market research; Personal communication from J. Black, et al, Stanford Sleep Patient Survey

ADX-N05: Significant Commercial Opportunity
Approximately 18 Million Moderate-to-Severe OSA Patients in the U.S.[1]



- ***OSA is a large and growing condition***
- ***Despite therapy, many OSA patients' EDS is not well controlled***

OSA = Obstructive Sleep Apnea, CPAP = Continuous Positive Airway Pressure, EDS = Excessive Daytime Sleepiness

Source: [1] Peppard PE, et al. *Am J Epidemiol.* 2013 Apr 14; [2] Primary market research; [3] Launois, SH, et al. *Current Opinion in Pulmonary Medicine.* 19(6):601-608, November 2013.

Financial Terms of Transaction

Jazz Pharmaceuticals®
Innovation that performs

Financial Terms

Offer Details	✓ Upfront payment of $125M in cash to Aerial BioPharma
Milestones	✓ Potential of up to $272M in milestone payments to Aerial BioPharma and SK Biopharmaceuticals ✓ Dependent upon successful completion of certain development milestones, obtaining marketing approval and reaching specific commercial sales milestones
Royalties	✓ Upon commercialization, royalties to Aerial BioPharma and SK Biopharmaceuticals ✓ The combined royalty rate increases with product sales; range is from high single digits to mid-teens

Jazz Pharmaceuticals®

Innovation that performs